NovoCure (NVCR) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
NovoCure (NVCR) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 17.54% |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn | 35.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.15% |
| Mar 31, 2026 | -10.27% |
| Dec 31, 2025 | 13.08% |
| Sep 30, 2025 | -11.93% |
| Jun 30, 2025 | -18.69% |
| Mar 31, 2025 | -94.74% |
| Dec 31, 2024 | -35.57% |
| Sep 30, 2024 | -32.56% |
| Jun 30, 2024 | -31.61% |
| Mar 31, 2024 | -110.97% |
| Dec 31, 2023 | -126.21% |
| Sep 30, 2023 | -94.25% |
| Jun 30, 2023 | -232.30% |
| Mar 31, 2023 | -148.94% |
| Dec 31, 2022 | -120.75% |
| Sep 30, 2022 | -150.77% |
| Jun 30, 2022 | -166.39% |
| Mar 31, 2022 | 27.41% |
| Dec 31, 2021 | -19.18% |
| Sep 30, 2021 | -3.92% |